Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Lung Cancer ; 72(1): 59-63, 2011 Apr.
Article in English | MEDLINE | ID: mdl-20728237

ABSTRACT

BACKGROUND: More than 50% of brain metastases (BMs) occur in advanced non-small cell lung cancer (NSCLC) patients. Untreated patients with BMs have a poor prognosis with a median survival of 2 months. In most cases BMs are multiple and their optimal therapy is whole-brain radiation therapy (WBRT). The role of systemic therapies for these patients is still a matter for investigation due to concerns about the ability of these drugs to cross the blood-brain barrier (BBB). Cisplatin (CDDP) remains the backbone for medical treatment of NSCLC and fotemustine (FTM) is a nitrosurea able to cross the BBB. METHODS: Patients with advanced NSCLC, ECOG performance status (PS) 0-1 and multiple BMs not amenable to surgery or stereotactic radiotherapy were treated with 2 cycles of FTM 80 mg/m(2) days 1, 8 and CDDP 80 mg/m(2) day 1, every 3 weeks followed by WBRT 30 Gy (3 Gy daily in 10 fractions). Radiological restaging was performed before WBRT to assess the role of chemotherapy both for cranial and extracranial disease. Patients with disease control (DC: complete response plus partial response) received 4 more cycles. To assess the basic activities of daily living (ADL), the Barthel ADL Index was used to score patients' performance every 2 cycles. The trial design provides a two-step evaluation according to the optimal two-stage design of Simon. In the first phase 29 patients were enrolled in order to verify if this schedule showed more than 25% response rate both for cranial and extracranial disease. If so, enrollment added up to a total of 81 patients. RESULTS: After the first evaluation 4 out of 29 patients were excluded from the study (3 untreated/1 not included for administrative reasons). At the time of the planned interim analysis patient's characteristics were the following: median age 61 years (range 44-70), M/F = 16/9, adenocarcinoma 11, squamous 5, large cell 2, undefined NSCLC 7; PS 0/1 in 11/14 cases, median Barthel Index score was 20 [13-20]. Three (12%) partial responses were observed, 9 subjects (36%) with stable disease and 13 (52%) showing disease progression. These data did not satisfy the pre-planned hypothesis and the study was stopped. At the time of the first evaluation before WBRT 12/25 (48%) patients had a systemic DC in contrast with 15/25 (60%) patients with BMs DC. Chemotherapy was relatively well tolerated with a prevalence of asthenia as the most relevant specific toxicity while the haematological toxicity was mild. CONCLUSION: CDDP and FTM combined with WBRT do not represent a therapeutic option for patients with NSCLC. Therefore further studies to evaluate the combination of systemic treatments with WBRT are warranted.


Subject(s)
Antineoplastic Agents/therapeutic use , Brain Neoplasms , Carcinoma, Non-Small-Cell Lung , Cisplatin/therapeutic use , Lung Neoplasms , Nitrosourea Compounds/therapeutic use , Organophosphorus Compounds/therapeutic use , Adult , Aged , Antineoplastic Agents/adverse effects , Brain Neoplasms/drug therapy , Brain Neoplasms/radiotherapy , Brain Neoplasms/secondary , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/radiotherapy , Carcinoma, Non-Small-Cell Lung/secondary , Cisplatin/adverse effects , Combined Modality Therapy , Female , Humans , Italy , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Lung Neoplasms/radiotherapy , Male , Middle Aged , Nitrosourea Compounds/adverse effects , Organophosphorus Compounds/adverse effects , Treatment Outcome
2.
Br J Cancer ; 90(12): 2288-96, 2004 Jun 14.
Article in English | MEDLINE | ID: mdl-15162156

ABSTRACT

Pain is a highly distressing symptom for patients with advanced cancer. WHO analgesic ladder is widely accepted as a guideline for its treatment. Our aim was to describe pain prevalence among patients diagnosed with advanced non-small-cell lung cancer (NSCLC), impact of pain on quality of life (QoL) and adequacy of pain management. Data of 1021 Italian patients enrolled in three randomised trials of chemotherapy for NSCLC were pooled. QoL was assessed by EORTC QLQ-C30 and LC-13. Analgesic consumption during the 3 weeks following QoL assessment was recorded. Adequacy of pain management was evaluated by the Pain Management Index (PMI). Some pain was reported by 74% of patients (42% mild, 24% moderate and 7% severe); 50% stated pain was affecting daily activities (30% a little, 16% quite a bit, 3% very much). Bone metastases strongly affected presence of pain. Mean global QoL linearly decreased from 64.9 to 36.4 from patients without pain to those with severe pain (P<0.001). According to PMI, 616 out of 752 patients reporting pain (82%) received inadequate analgesic treatment. Bone metastases were associated with improved adequacy and worst pain with reduced adequacy at multivariate analysis. In conclusion, pain is common in patients with advanced NSCLC, significantly affects QoL, and is frequently undertreated. We recommend that: (i). pain self-assessment should be part of oncological clinical practice; (ii). pain control should be a primary goal in clinical practice and in clinical trials; (iii). physicians should receive more training in pain management; (iv). analgesic treatment deserves greater attention in protocols of anticancer treatment.


Subject(s)
Carcinoma, Non-Small-Cell Lung/complications , Lung Neoplasms/complications , Pain Management , Pain/epidemiology , Adult , Aged , Aged, 80 and over , Bone Neoplasms/complications , Bone Neoplasms/secondary , Carcinoma, Non-Small-Cell Lung/secondary , Female , Humans , Italy , Lung Neoplasms/pathology , Male , Middle Aged , Pain/etiology , Pain Measurement , Prevalence , Quality of Life , Randomized Controlled Trials as Topic , Severity of Illness Index
3.
Oncol Rep ; 8(5): 1111-5, 2001.
Article in English | MEDLINE | ID: mdl-11496326

ABSTRACT

The aim of this phase II multicenter trial was to evaluate the activity of a novel combination of gemcitabine (GEM) and epirubicin (EPI) in advanced pancreatic cancer patients. Clinical benefit and response rate were the main efficacy end-points. From December 1997 to October 1999, 30 consecutive patients with measurable advanced pancreatic cancer were enrolled. Gemcitabine was administered intravenously in 30 min at a dose of 800 mg/m2 on days 1, 8, 15 followed by i.v. injection of epirubicin 25 mg/m(2); treatment was repeated every 28 days. With regard to clinical benefit response, 8/21 patients (38%) experienced significant palliation of tumor-related symptoms; the median symptom control time was 25 weeks. No complete responses were recorded while 6 patients achieved a partial remission, for an overall response rate of 20%; 10 patients (30%) had a stable disease and 14 (46%) had progressive disease. The median time to progression was 14 weeks. Median survival was 26 weeks, with 6 patients (20%) having long-term survival at 46 weeks. In general, chemotherapy was well tolerated; 9 patients (30%) suffered from WHO grade 3-4 haematological toxicity and 5 patients (16.6%) suffered from grade 3 non-haematological toxicity. In conclusion, the GEM plus EPI regimen represent a feasible approach for improvement of clinical benefit in advanced pancreatic cancer patients, but confirmatory investigations are required.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Pancreatic Neoplasms/drug therapy , Adenocarcinoma/mortality , Adenocarcinoma/secondary , Adult , Aged , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Disease Progression , Epirubicin/administration & dosage , Female , Humans , Male , Middle Aged , Neoplasm Staging , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Treatment Outcome , Gemcitabine
4.
Clin Ter ; 133(6): 401-4, 1990 Jun 30.
Article in Italian | MEDLINE | ID: mdl-2147885

ABSTRACT

There are no univocal experimental data in literature about T cell clone alterations in the peripheral blood during Hashimoto's thyroiditis (TH), autoimmune disease, and during subacute thyroiditis (TSA), an inflammatory thyroid lesion with possibility of "self-perpetuation". The object of our research was to examine the T cell clones, soluble fraction of interleukin 2 receptor and HLA-DR modifications in patients with TH and TSA compared with healthy population. Our results show significant increase of sIL-2r in the TSA compared with normal subjects and with patients TH, where on the contrary, a constant increase of HLA-DR was observed.


Subject(s)
HLA-DR Antigens/analysis , Lymphocyte Subsets , Receptors, Interleukin-2/analysis , Thyroiditis, Autoimmune/blood , Thyroiditis, Subacute/blood , Adult , Female , Humans , Male , Middle Aged
5.
Clin Ter ; 133(3): 173-5, 1990 May 15.
Article in Italian | MEDLINE | ID: mdl-2142905

ABSTRACT

Lithium, a monovalent cation used mainly in the management of certain psychiatric disorders, appears to act on thyroid function and to interfere with T3 and T4 secretion. The authors have followed 10 patients treated with lithium salts for two years and have monitored some parameters of thyroid function. Clinical and laboratory signs of hypothyroidism appeared in one case and subsided after withdrawal of lithium treatment.


Subject(s)
Lithium/adverse effects , Mental Disorders/drug therapy , Thyroid Gland/drug effects , Adult , Female , Humans , Male , Middle Aged , Thyroid Gland/physiology
6.
Clin Ter ; 133(4): 227-31, 1990 May 31.
Article in Italian | MEDLINE | ID: mdl-2142910

ABSTRACT

Hashimoto's thyroiditis is an autoimmune disease characterized by the presence of thyroid autoantibodies and frequent coexistence of other autoimmune disorders. The object of our research was to examine the peripheral blood and fine-needle cytology modifications in patients with this disease during therapy with Timopentina. Our results suggested a possible therapeutic effect of Timopentina, as an alternative to traditional cortisone treatment.


Subject(s)
Antibodies/analysis , Peptide Fragments/therapeutic use , Thymopoietins/therapeutic use , Thymus Hormones/therapeutic use , Thyroiditis, Autoimmune/immunology , Adult , Biopsy, Needle , Female , Humans , Leukocyte Count , Lymphocytes/pathology , Middle Aged , Thymopentin , Thyroid Hormones/blood , Thyroiditis, Autoimmune/blood , Thyroiditis, Autoimmune/drug therapy , Thyroiditis, Autoimmune/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...